文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

评估巴西家族性高胆固醇血症遗传筛查索引病例中使用的临床和实验室参数。

Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil.

机构信息

Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, Brazil.

Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, Brazil.

出版信息

Atherosclerosis. 2017 Aug;263:257-262. doi: 10.1016/j.atherosclerosis.2017.06.917. Epub 2017 Jun 22.


DOI:10.1016/j.atherosclerosis.2017.06.917
PMID:28689098
Abstract

BACKGROUND AND AIMS: There is controversy on the accuracy of different diagnostic criteria for familial hypercholesterolemia (FH). The aim of this study is to assess the performance of different clinical criteria used to identify individuals for FH genetic cascade screening in Brazil. METHODS: All index cases (IC) registered in the Hipercol Brasil program between 2011 and 2016 were analyzed. Inclusion criteria were age ≥18 years and elevated LDL-cholesterol (LDL-C) levels, with a conclusive result in the genetic test, whether positive or negative. Initially, we tested the multivariable association between clinical and laboratory markers and the presence of an FH causing mutation. Then, we analyzed sensitivity, specificity, positive and negative predictive values for the LDL-C quartile distribution, LDL-C as a continuous variable, as well as the performance measures for the Dutch Lipid Clinic Network (DLCN) score to identify a mutation. RESULTS: Overall, 753 ICs were included and an FH causing mutation was found in 34% (n = 257) of the subjects. After multivariable analysis, LDL-C as a continuous variable, tendon xanthomas and corneal arcus were independently associated with the presence of FH mutations. LDL-C values ≥ 230 mg/dL (5.9 mmol/L) had the best tradeoff between sensitivity and specificity to diagnose a mutation. The DLCN score presented a better performance than LDL-C to identify a mutation, area under the ROC curve were 0.744 (95% CI: 0.704-0.784) and 0.730 (95% CI: 0.687-0.774), respectively, p=0.014. CONCLUSIONS: In our population, LDL ≥230 mg/dL is a feasible criterion to indicate ICs to genetic testing.

摘要

背景和目的:不同的家族性高胆固醇血症(FH)诊断标准的准确性存在争议。本研究旨在评估巴西用于 FH 遗传级联筛查的不同临床标准的性能。

方法:分析了 2011 年至 2016 年期间在 Hipercol Brasil 计划中登记的所有索引病例(IC)。纳入标准为年龄≥18 岁和 LDL-胆固醇(LDL-C)水平升高,遗传检测结果有结论,无论阳性或阴性。最初,我们测试了临床和实验室标志物与 FH 致病突变之间的多变量关联。然后,我们分析了 LDL-C 四分位分布、作为连续变量的 LDL-C 以及荷兰脂质诊所网络(DLCN)评分对识别突变的敏感性、特异性、阳性和阴性预测值。

结果:共纳入 753 例 IC,其中 34%(n=257)的患者存在 FH 致病突变。经过多变量分析,连续变量的 LDL-C、腱黄瘤和角膜弓与 FH 突变的存在独立相关。LDL-C 值≥230mg/dL(5.9mmol/L)在诊断突变的敏感性和特异性之间具有最佳的权衡。DLCN 评分在识别突变方面优于 LDL-C,ROC 曲线下面积分别为 0.744(95%CI:0.704-0.784)和 0.730(95%CI:0.687-0.774),p=0.014。

结论:在我们的人群中,LDL-C≥230mg/dL 是指示 IC 进行基因检测的可行标准。

相似文献

[1]
Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil.

Atherosclerosis. 2017-6-22

[2]
Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: Clinical, genetic and atherosclerotic burden profile.

Nutr Metab Cardiovasc Dis. 2018-1

[3]
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study.

Atherosclerosis. 2018-10

[4]
Dutch Lipid Clinic Network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population.

Arch Cardiovasc Dis. 2015-10

[5]
Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland.

Atherosclerosis. 2016-6

[6]
Health related quality of life in individuals at high risk for familial hypercholesterolemia undergoing genetic cascade screening in Brazil.

Atherosclerosis. 2018-10

[7]
Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review.

Atherosclerosis. 2018-10

[8]
Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.

Atherosclerosis. 2015-5

[9]
The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.

Dan Med Bull. 2002-11

[10]
Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia.

Atherosclerosis. 2016-3

引用本文的文献

[1]
Prevalence and factors associated with possible cases of familial hypercholesterolemia in Brazilian adults: a cross-sectional study.

Sci Rep. 2023-11-22

[2]
Opportunistic Genetic Screening for Familial Hypercholesterolemia in Heart Transplant Patients.

J Clin Med. 2023-2-3

[3]
Clinical Evaluation of Patients with Genetically Confirmed Familial Hypercholesterolemia.

J Clin Med. 2023-1-29

[4]
Polygenic risk score for hypercholesterolemia in a Brazilian familial hypercholesterolemia cohort.

Atheroscler Plus. 2022-6-28

[5]
Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics.

J Atheroscler Thromb. 2023-10-1

[6]
Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles.

J Endocr Soc. 2019-10-11

[7]
Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease.

J Transl Med. 2018-12-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索